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Fast biodegradable (12 h < half-life < 48 h) radioactive labeled microspheres are needed for PET and SPECT lung perfusion
and radiomicrosphere therapy planning. An emulsion method was used to create 30.1 ± 4.8 𝜇m size range microspheres with
biodegradable Chitosan glycol (CHSg). Microspheres were characterized and labeled with 99mTc or 68Ga as an alternative to MAA
in perfusion PET and SPECT studies. Surface decoration of CHSgmicrospheres with p-SCN-Bn-NOTAwas performed to increase
68Ga in vivo stability. 99mTc was labeled directly to the CHSgmicrospheres. Labeling yield and in vitro radiochemical stability were
evaluated. In vitro CHSg microsphere degradation half-life was ∼24 hours in porcine blood. Labeled microspheres were injected
into Sprague Dawley rats and biodistribution was determined after 2 and 4 hours. Both 99mTc-CHSg and 68Ga-NOTA-CHSg were
quickly allocated in the lungs after injection. 99mTc-CHSg showed 91.6 ± 6.5% and 83.2 ± 4.1% of the decay corrected injected
activity remaining in the lungs after 2 and 4 hours, respectively. For the obtained 68Ga-NOTA-CHSgmicrospheres, lung allocation
was very high with 98.9 ± 0.2% and 95.6 ± 0.9% after 2 and 4 hours, respectively. The addition of p-SCN-Bn-NOTA acts as a
radioprotectant eliminating the released 68Ga activity from the lungs to the bladder protecting the other organs.
1. Introduction
Since 1974, the use of 99mTc-MAA (macroaggregated albu-
min) has been established as the gold standard for lung per-
fusion studies [1].The availability of aMAA lyophilized kit [1]
and the 99Mo/ 99mTc radio-isotopic generator [2] facilitated
the use of 99mTc-MAA as a lung perfusion agent. The ori-
entation of macroaggregates (which are seldom spherical) in
the blood flow stream is important for determining “effective
size,” making it difficult to predict their in vivo behavior.
Aggregates rupturing into smaller pieces add another factor
making the size distribution variable and unreliable [3]. The
ideal (theoretical) perfusion particle should be spherical (size
not to be dependent on particle orientation) with a practical
size distribution of 30 ± 10 𝜇m [3]. Polymeric spherical
microparticles with narrow size distributions have been
previously obtained [4].The use of polymerical microspheres
will also eliminate the risk of disease transmission due to
human derived materials (such as MAA).
Another important application of 99mTc-MAA is in the
radiomicrosphere therapy (RMT) planning [5]. Nonspherical
macroaggregates (MAA, 10–90𝜇m) are used to predict the
distribution behavior of the perfectly spherical therapy parti-
cles used for RMT which are commercially available (SirTEX
and TheraSpheres ≈ 30 ± 10 𝜇m). Despite the differences in
size and morphology, MAA prediction of particle allocation
has been shown to be a valuable tool in RMT planning;
however, whether a better planning agent can ultimately
produce a better clinical outcome is still an open question.
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Many of the available biocompatible polymers have
been labeled with 99mTc. Some examples are 99mTc-PLGA
(poly (DL-lactide-co-glycolide)) nanoparticles [6], 99mTc-
PLA (poly lactic acid) [7], and 99mTc-CHS (Chitosan) [8]
among others. PLGA and PLA have known long degradation
times (months). CHS has been found to have an in vitro half-
life greater than 21 days [9]. This characteristic is relatively
undesired when performing lung perfusion studies or for
RMT planning, as the particles need to degrade fast (maxi-
mum 48 hour half-life) and restore normal blood flow.
A chitin derivate polysaccharide, chitosan (CHS), has
recently emerged as a good material for drug delivery
applications [10]. There are several commercially available
CHSmaterials with both high and low solubility in water [11].
Particle degradation half-life is directly related to solubility
of the polymer. There is a compromise in the ideal particle
degradation rate: it has to be slow enough to allow allocation
in the lungs and subsequent imaging, but fast enough to
clear the vessels and restore blood flow afterwards (half-life
12–48 hours). One of the best candidates is Chitosan glycol
(CHSg). CHSg has moderate (2mg/mL) solubility in water,
is well characterized, and commercially available (Sigma-
Aldrich, CHSg ≥ 60%). Degradation can be manipulated
using glutaraldehyde as a crosslinking agent.
Another important limitation of RMT planning is the
difficulty quantifying biodistribution for dosimetric calcula-
tions when 99mTc is used. This is due to the fact that the
99mTc-MAA scintigraphy is a single photon emission tomog-
raphy technique (SPECT) and creates difficulty in obtaining
proper attenuation correction as compared to positron emis-
sion tomography (PET). The RMT planning will be greatly
benefited by the inclusion of a positron emitter radioisotope,
since absolute attenuation correction and potentially superior
spatial and temporal resolution are available with PET.
Important advances were made in early years by labeling
the Pulmolite MAA kit with 68Ga [12–14], obtaining an 80%
labeling yield and purity >95%. However since MAA is a
poor surrogate of therapeutic microspheres, there is a need
for fast biodegradable (12 h < half-life < 48 h) microspheres
(30±10 𝜇m) that can be labeled with a PET isotope for proper
RMT planning.
2. Materials and Methods
2.1. Particle Preparation and Surface Decoration. CHSg
(Sigma-Aldrich, USA) particles were prepared using the
water in oil (w/o) emulsion technique. One mL of CHSg
solution (2%w/v solution in 2% v/v Acetic Acid) was added
dropwise to a round bottom flask containing an egg-shaped
magnetic stirrer, 20mL of toluene, and 100𝜇L of Tween
80 (surfactant). Magnetic stirring rate was set at 1150 rpm
(Model PC-410D, Corning-Cole Palmer, USA).The emulsion
was stabilized for 15 minutes and 100 𝜇L of glutaraldehyde
(FisherSci, USA) was added. Stirring was continued for
another 105 minutes. Later, toluene was decanted. Particles
were washed three times with 200-proof ethanol (Sigma-
Aldrich, USA) and centrifuged (1000 rcf, 30 seconds); the
supernatant was removed and finally lyophilized for labeling
(Model Freeze One Plus 6, LabConco, USA).
A stock solution of p-SCN-Bn-NOTA (Macrocyclics,
USA) with concentration 1mg/mL in Na
2
HCO
3
/NaH
2
CO
3
(pH 9.3-9.4, Sigma-Aldrich, USA) was prepared. Micro-
spheres were resuspended in 1mL of the p-SCN-Bn-NOTA
Stock solution. The suspension was stirred at room tempera-
ture for 4, 12, 24 and 48 hours (𝑛 = 3 per time point) to form
theNOTA-CHSg particles [15]. After p-SCN-Bn-NOTA reac-
tion, particles were washed 3 times with 200-proof ethanol
and centrifuged (1000 rcf, 30 seconds); the supernatant was
removed and finally lyophilized for labeling (Model Freeze
One Plus 6, LabConco, USA). The reaction (Figure 1) yield
was evaluated using a UV/Visible spectrophotometer (Cary
100 Bio, Varian/Agilent Technologies, Switzerland) at the
224 nm absorption peak of the p-SCN-Bn-NOTA.
2.2. 99𝑚𝑇𝑐-CHSg 68Ga-CHSg and 68Ga-NOTA-CHSg Label-
ing. NA 99mTcO
4
was obtained from a local pharmacy
(Triad Isotopes, Miami, USA). One mCi was used to label
approximately 100,000 particles in a 15mL centrifuge vial
containing the lyophilized particles after addition of 100𝜇L
of 1mg/mL SnCl
2
stock solution (Sigma-Aldrich, USA).
99mTc-CHSg labeling was performed during 30 minutes at
25∘C and 750 rpm in a Thermomixer (Comfort 15mL Block
Thermomixer, Eppendorf, Germany). 68Ga was obtained by
eluting the IGG-100 (Eckert and Ziegler, 50mCi) 68Ge/68Ga
generator with 5mL of 0.1M HCl solution (starting solution
for buffering). 68Ga Labeling of 68Ga-NOTA-CHSg (pH ≈ 4,
0.25mL of 3N NaAc added to initial solution) and 68Ga-
CHSg (pH ≈ 5.5, 0.3mL of 3N NaAc added to initial solu-
tion) was performed at room temperature for 15 minutes.
Particles were later centrifuged (1000 rcf, 30 seconds) and
the supernatant was removed using a 5󸀠󸀠 spinal needle. Both
particles and supernatant were measured for labeling yield
determination and radiochemical purity studies.
Labeled particles (𝑛 = 4) were resuspended in recon-
stituted (1%w/v) bovine hemoglobin lysate (Sigma-Aldrich,
USA). Particles were stirred for 4 hours at 37∘C in a
thermomixer. Every hour the particles were centrifuged,
decanted, and measured together with the supernatant to
assess radiochemical stability.
2.3. CHSg Microspheres Degradation Studies. For the in vitro
particle degradation studies, porcine blood was obtained
from a local abattoir (Mataderos Cabrera, Miami, USA),
sodium citrate was added as anticoagulant, and the blood
was centrifuged at 3000 rcf for 30 minutes. Plasma was later
decanted and used formicrosphere degradation experiments.
Lyophilized CHSg and NOTA-CHSg (unlabeled) were resus-
pended in the plasma. CHSg and NOTA-CHSg microsphere
samples were extracted at 1, 2, 4, 12, 24, 48, and 72 hours.
All samples (𝑛 = 3 per time point) were analyzed for size
distribution and particle concentration using a hemacytome-
ter (Reichert, USA) and an optical microscope (Micromaster,
FisherSci, USA).
For in vivo particle degradation studies, lyophilized
CHSg microparticles were resuspended in carbonate buffer
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Figure 1: Surface decoration of CHSgmicroparticles with p-SCN-Bn-NOTA. R1 and R2 are repeated CHSg polymer chains (equal or different
lengths).
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Figure 2: CHSg + NHS-Fluorescein reaction. R1 and R2 are repeated CHSg polymer chains (equal or different lengths).
(pH = 9.34). NHS-Fluorescein (Thermo Scientific, USA) was
dissolved in dimethyl sulfoxide (DMSO, Thermo Scientific,
USA)with a concentration of 10mg/mL. A total 1mg ofNHS-
fluorescein (100 𝜇L of the stock solution) was added to the
vial containing the particles and stirred for 2 hours (Figure 2).
At the end of the reaction particles were centrifuged, washed
three times with water, and finally lyophilized (lyophilized
CHSg-fluorescein).
Particles were resuspended in saline solution for injection
(FisherSci, USA) and ≈10000 particles were injected to each
Sprague Dawley rat (200–225 grams, Harlan, USA) in the
lateral tail vein. Animals were euthanized at 2, 6, 12, and 24
hours (𝑛 = 2 per time point). Before extraction of the lungs,
the trachea was isolated and a V cut was made. A syringe
containing optimal cutting temperature (OCT, Tissue-Tek,
USA) cryoembedding media was inserted in the trachea and
the lungs were filled with 2mL. Lungs were finally extracted
and frozen in a plastic mold filled with OCT and dipped in
liquid nitrogen. Specimens were obtained by cryosectioning
the frozen samples (14 𝜇m slices) in a Microtome (Leica,
Japan). Lung cryospecimens (4 lung sections per animal)
were analyzed with a florescence microscope (Olympus IX81
with a Q Imaging Retiga 1300 Camera, USA). The entire area
of each specimen was imaged using a 4x objective. Obtained
images were analyzed using in-house software and particles
were measured and counted.
2.4. Lung Perfusion Experiments. Animals (Sprague Dawley
rats, 200–225 grams, 2 per time point, Harlan, USA) were
weighed before the procedure and anesthetized using an
Ohmeda Isotec 3 isoflurane vaporizer (GE Healthcare, USA).
Animals were restrained in the supine position (completely
anesthetized) and a torso X-ray was obtained (Belmont
Acuray 071A, USA). Later, 100 𝜇L of the labeledmicrospheres
(8,000–10,000 particles) with an activity ranging from 1.85 to
3.7MBq (50 to 100𝜇Ci) was injected through the lateral tail
vein. Animals were euthanized at 2 or 4 hours. For both time-
points lungs, liver, spleen, heart, kidneys, ribs, and 0.2mL
of blood and urine were collected, weighed, and measured
for activity using a Cobra 5000 well counter (Packard, USA).
Noncollimated autoradiography images (in the unaltered
supine position the X-ray was obtained) were also taken at
1, 2, 3, and 4 hours (Packard Phosphorimager, Perkin Elmer,
USA). In one group free 68Ga was injected as a control.
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30 𝜇m
Figure 3: Prepared CHSg microspheres.
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The obtained X-rays and the autoradiography images were
superimposed to provide anatomical and functional data.
3. Results and Discussion
3.1. Particle Preparation and Characterization. The emulsion
method used created spherical particles (Figure 3). A size
distribution of 30 ± 5 𝜇m was obtained.
Lyophilization and labeling of the particles did not affect
their size and morphology. CHSg microspheres swelled 20–
25% when placed in contact with water, a feature that was
taken into consideration when producing these particles.
The distribution did not change after the 12-hour reaction
with p-SCN-Bn-NOTA (Figure 1) (𝑃 = 0.1, 95% confidence).
The final size distribution obtained was 31 ± 5 𝜇m (Figure 4).
However many broken particles (no longer spherical) and
small fragments were observed due to rupture of the original
CHSg microspheres after 24 and 48 hours of p-SCN-Bn-
NOTA reaction.
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Figure 5: Surface decoration of CHSg with p-SCN-Bn-NOTA
reaction yield at different reaction times.
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Around 260 ± 15 𝜇g of p-SCN-Bn-NOTA (of the total
1mg added, 𝑛 = 3) was covalently attached to the surface
of the CHSg microspheres after 12 hours of reaction. The net
p-SCN-Bn-NOTA amount that bonded to the microspheres
surface was increased to 297±25 and 347±40 𝜇g after 24 and
48 hours of reaction (Figure 5).
Maximum reaction yield taking into consideration the
totality of available NH
2
groups was slightly over 1%. Nev-
ertheless it is a skewed calculation since only a fraction of
these groups are exposed for the p-SCN-Bn-NOTA reaction.
Regardless of the yield, the addition of 260 micrograms of p-
SCN-Bn-NOTA to the batch represents a theoretical loading
capacity (assuming 95% labeling yield) of 12.8 𝜇Ci/particle
(1.28 Ci for 100,000 particles). In molecular imaging only
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Figure 7: Porcine plasma microsphere degradation studies for (a) CHSg and (b) CHSg-NOTA (𝑛 = 3).
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Figure 8: CHSgmicrospheres in vivo degradation studies (𝑛 = 2 per
time point).
3–5mCi is used, 3 orders of magnitude less than the total
available capacity.
3.2. 99𝑚𝑇𝑐-CHSg 68Ga-CHSg and 68Ga-NOTA-CHSg Labeling
and In Vitro Stability. Labeling yields of 94.7 ± 0.1%, 96.0 ±
3.5%, and 97.4 ± 3.0% for 99mTc-CHSg, 68Ga-CHSg, and
68Ga-NOTA-CHSg, respectively, were obtained (Figure 6).
Over 97% radiochemical purity was found at all times for
68Ga-CHSg and 68Ga-NOTA-CHSg during the 4-hour study.
Within the first hour 99mTc-CHSg microparticles quickly
decreased in radiochemical purity to 82%, remaining fairly
constant afterwards (being 80% after 4 hours) (Figure 6).
Radiochemical purity in saline solution and PBS buffer
was over 90% for 99mTc-CHSg, 68Ga-CHSg, and 68Ga-
NOTA-CHSg after four hours. Even though the in vitro
radiochemical purity of 99mTc-CHSg decreased rapidly to
80% in 1% reconstituted hemoglobin lysate one hour after
labeling, the particles were tested in animals. For lung per-
fusion particles allocated in the vessels, the occlusion locally
reduces the fluid in contact with the particles, potentially
reducing the detachment of the 99mTc label and therefore
increasing the chances of a successful image. Because of the
high labeling yield obtained for 99mTc-CHSg (96.1 ± 0.3%)
the particles did not need postlabeling purification.
3.3. CHSgMicrospheres Degradation Studies. Porcine plasma
studies showed fast (≈24 hours) microsphere degradation
half-life (Figure 7). CHSg particles are initially swollen in
plasma (effect not observed in PBS buffer or saline solution).
The dramatic increase observed in particle concentration
after 12 hours, together with the decrease in average particle
size, is due to the rupture of the original particles into smaller
fractions. These fractions are later dissolved (degraded) dis-
appearing gradually from the suspension.The observed half-
lives for CHSg and CHSg-NOTA were similar (≈24 hours),
and there was no significant difference in their degradation
profiles.
Particle degradation experiments performed in vivo show
a similar degradation mechanism to that obtained in vitro
(Figure 8).
Particle concentration is initially increased because of
microspheres rupture. Smaller pieces are later slowly dis-
solved. This dissolution results in a steady decrease of the
particles average diameter and also in particle concentration
in tissue (Figure 9). The in vivo half-life of the particles
was determined to be 18–20 hours, since the time when
the particle concentration is reduced to half (50% of initial
particle concentration of any size occluding lung capillaries).
Results obtained in the in vivo experiments are highly
qualitative since many assumptions were made for the calcu-
lations of average size and concentration. Particles concen-
tration was assumed to be homogeneous in the entire lung,
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Figure 9: Representation of the in vivo CHSg microsphere degradation mechanism. Collage of representative microarticles found in the
cryosections for different time points: (a) 2 hours, (b) 6 hours, (c) 12 hours, and (d) 24 hours. Relative particle amount in the images is related
to the real particle concentration found in the tissue sections.
and particles under 10 micrometers were not included in
the analysis since those should no longer occlude the vessels
and therefore will not interfere with the later injection of the
therapeutic particles in the final RMTphase of the procedure.
Furthermore, the average size calculation is only an
estimate due to the artifacts inherent in the cryosectioning
method; there is no way to know if a particle that is sized
represents the whole cross-section or only a part of the par-
ticle, the latter being more likely. Therefore, the particle size
distribution is probably an underestimate of the true in vivo
size distribution. Nevertheless, by 24 hours, comparatively
few particles were observed in the sections. Also, no particle
clumping was observed as the particles were found to be
evenly distributed and thus a good estimation of particles
half-life was obtained. The particle degradation half-life was
found to be between 18 and 20 hours, which makes the
CHSg microspheres a potential candidate for lung perfusion
imaging and RMT planning.
3.4. Lung Perfusion Experiments. Following tail vein injec-
tion, most of the 99mTc-CHSg activity was allocated in
the lungs within the first 30 seconds (checked with Geiger
counter, Victoreen ASM-990, Fluke, USA). After 2 hours,
91.6 ± 6.5% of the injected activity (decay corrected) was
allocated in the lungs, and after 4 hours 83.2 ± 4.1% was still
found in the lungs, as measured using a gamma-well counter
(Cobra 5000well counter, Packard, USA) (Table 1).The activ-
ity released from the lungs was almost exclusively excreted
to the urine accounting for 4.9 ± 2.5% and 10.0 ± 2.1%
decay corrected injected dose (DC-ID) after 2 hours and 4
hours, respectively. Less than 3% DC-ID/organ was detected
in all the other organs at any given time point (Table 1).
Lung perfusion images were obtained at several time points
confirming the preferential lung allocation (Figure 11).
Despite the excellent in vitro results obtained, 68Ga-CHSg
did not perform well as a lung perfusion imaging agent.
Strong evidence of 68Ga transchelation by native transferrin
was observed (Figure 10).
Nevertheless, 68Ga-CHSg in vivo behavior was notably
different from that of free 68Ga 2 hours after injection. After
2 hours 31.9 ± 1.3% DC-ID from the 68Ga-CHSg can be
International Journal of Molecular Imaging 7
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Figure 10: Comparison of images 10 minutes after injection for (a) free 68Ga and (b) 68Ga-CHSg.
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Figure 11: Uncollimated, non-decay-corrected full body X-ray/autoradiography of 99mTc-CHSg and 68Ga-NOTA-CHSg at 1, 2, 3, and 4 hours
following injection.
found in the lungs (Table 1), compared to the 3.1 ± 2.9%
for the free 68Ga, but 46.7 ± 1.2% of the activity from the
68Ga-CHSg was already released to the blood. The 68Ga
release from the CHSg to the blood was not expected since
in vitro experiments showed minute leaching. This result
(release of isotope from 68Ga-CHSg) made it necessary to
coat the surface of the CHSg microspheres with a 68Ga
specific chelator (NOTA) to increase in vivo stability of the
labeling. Animal experiments performed with 68Ga-NOTA-
CHSg showed high lung allocation and stability during the
4-hour study (Figure 11).
After 2 hours 98.9 ± 0.2% DC-ID of 68Ga-NOTA-CHSg
was found in the lungs, decreasing to 95.6 ± 0.9% after 4
hours. The activity released from the lungs moved directly
to the bladder (3.5 ± 0.6% after 4 hours). The absence of
activity in the blood (0.1 ± 0.1% DC-ID at 2 hours and 0.5 ±
0.1%DC-ID after 4 hours) evidenced the high radiochemical
stability of the NOTA-68Ga complex. The activity found in
the urine must be due to early particle degradation releasing
small polar fragments as frag-NOTA-68Ga. The addition of
the NOTA chelator to the surface of the particles also served
as an apparent radioprotectant to the rest of the organs, since
less than one percent DC-ID was found in the blood at
any given time. From the images (Figure 11) and the organ
biodistribution data (Table 1), it can be concluded that in
vivo stability of the prepared 68Ga-NOTA-CHSg and 99mTc-
CHSg is remarkable and the labeled microspheres are good
candidates for PET and SPECT lung perfusion imaging,
respectively.
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Table 1: Biodistribution for 99mTc-CHSg and 68Ga-NOTA-CHSg at 2 and 4 hours and 68Ga-CHsg at 2 hours expressed as percent of decay
corrected injected dose per organ (% DC-ID/organ).
Organs
Biodistribution in % DC-ID/organ
68Ga-NOTA-CHSg 99mTc-CHSg 68Ga-CHSg Free 68Ga
2 hours 4 hours 2 hours 4 hours 2 hours 2 hours
Spleen 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.9 ± 0.2 0.6 ± 0.5
Blood 0.1 ± 0.1 0.5 ± 0.1 0.7 ± 0.5 0.8 ± 0.1 46.7 ± 1.2 84.9 ± 4.5
Rib 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.0 0.5 ± 0.4
Urine 0.5 ± 0.4 3.5 ± 0.6 4.9 ± 2.5 10.0 ± 2.1 10.9 ± 0.1 6.8 ± 2.9
Right kidney 0.1 ± 0.0 0.1 ± 0.0 1.1 ± 1.0 2.6 ± 0.8 0.9 ± 0.2 0.5 ± 0.5
Left kidney 0.1 ± 0.0 0.1 ± 0.0 1.2 ± 1.1 2.6 ± 0.8 0.8 ± 0.3 0.5 ± 0.5
Heart 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.2 ± 0.2 0.7 ± 0.7
Total lungs 98.9 ± 0.2 95.6 ± 0.9 91.6 ± 6.5 83.2 ± 4.1 31.9 ± 1.3 3.1 ± 2.9
Total liver 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.3 0.7 ± 0.3 6.3 ± 0.7 2.3 ± 1.9
Bold highlights the most important target organs. It is necessary to keep most of the activity in the lungs while the blood stays clear.
4. Conclusions
Chitosan glycol microspheres within the desired 30 ± 10 𝜇m
size range (to act as surrogates for the commercial SirSpheres
and TheraSpheres, for treatment planning) were successfully
obtained. Labeling was performed with >90% yield and in
vitro radiochemical stability after 4 hours. High in vitro radio-
chemical purity was found for the labeled particles in the 4
hour study. In vitro degradation half-life was found to be ≈24
hours in porcine plasma, while in vivo half-life of the particles
was found to be 18–24 hours. Both 99mTc-CHSg and 68Ga-
NOTA-CHSg showed lung allocation quickly after injection.
Biodistribution showed 91.6 ± 6.5% DC-ID and 83.2 ± 4.1%
DC-ID of the 99mTc-CHSg injected activity remaining in
the lungs after 2 and 4 hours, respectively. Lung allocation
was very high for 68Ga-NOTA-CHSg microspheres, with
98.9 ± 0.2% DC-ID and 95.6 ± 0.9% DC-ID after 2 and 4
hours, respectively.The addition of p-SCN-Bn-NOTA acts as
a 68Ga radioprotectant, since the microspheres degradation
products are quickly eliminated to the bladder protecting the
other organs, contrary to free 68Ga which remains in the
blood pool bound to native transferrin.
Abbreviations
MAA: Macroaggregated albumin
PET: Positron emission tomography
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NOTA: 1,4,7-triazacyclononane-1,4,7-triacetic
acid
p-SCN-Bn-NOTA: S-2-(4-Isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic
acid.
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